**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 81025

**Manuscript Type:** MINIREVIEWS

**New trends in the surgical management of soft tissue sarcoma: The role of preoperative biopsy**

Pavlidis ET *et al*. Soft tissue sarcoma

Efstathios T Pavlidis, Theodoros E Pavlidis

**Efstathios T Pavlidis, Theodoros E Pavlidis,** 2nd Propedeutic Department of Surgery, Hippocration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece

**Author contributions:** Pavlidis TE designed research, contributed new analytic tools, analyzed data and review; Pavlidis ET performed research, analyzed data review and wrote the paper.

**Corresponding author: Theodoros E Pavlidis, Doctor, PhD, Full Professor, Surgeon,** 2nd Propedeutic Department of Surgery, Hippocration Hospital, School of Medicine, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, Greece. pavlidth@auth.gr

**Received:** October 21, 2022

**Revised:** December 26, 2022

**Accepted:** January 9, 2023

**Published online:** February 24, 2023

**Abstract**

Soft tissue sarcoma (STS) accounts for 1% of all malignant neoplasms in adults. Their diagnosis and management constitute a challenging target. They originate from the mesenchyme, and 50 subtypes with various cytogenetic profiles concerning soft tissue and bones have been recognized. These tumors mainly affect middle-aged adults but may be present at any age. Half of the patients have metastatic disease at the time of diagnosis and require systemic therapy. Tumors above 3-5 cm in size must be suspected of potential malignancy. A thorough history, clinical examination and imaging that must precede biopsy are necessary. Modern imaging techniques include ultrasound, computed tomography (CT), new magnetic resonance imaging (MRI), and positron emission tomography/CT. MRI findings may distinguish low-grade from high-grade STS based on a diagnostic score (tumor heterogeneity, intratumoral and peritumoral enhancement). A score ≥ 2 indicates a high-grade lesion, and a score ≤ 1 indicates a low-grade lesion. For disease staging, abdominal imaging is recommended to detect early abdominal or retroperitoneal metastases. Liquid biopsy by detecting genomic material in serum is a novel diagnostic tool. A preoperative biopsy is necessary for diagnosis, prognosis and optimal planning of surgical intervention. Core needle biopsy is the most indicative and effective. Its correct performance influences surgical management. An unsuccessful biopsy means the dissemination of cancer cells into healthy anatomical structures that ultimately affect resectability and survival. Complete therapeutic excision (R0) with an acceptable resection margin of 1 cm is the method of choice. However, near significant structures, *i.e.*, vessels, nerves, an R2 resection (macroscopic margin involvement) preserving functionality but having a risk of local recurrence can be an acceptable choice, after informing the patient, to prevent an unavoidable amputation. For borderline resectability of the tumor, neoadjuvant chemo/radiotherapy has a place. Likewise, after surgical excision, adjuvant therapy is indicated, but chemotherapy in nonmetastatic disease is still debatable. The five-year survival rate reaches up to 55%. Reresection is considered after positive or uncertain resection margins. Current strategies are based on novel chemotherapeutic agents, improved radiotherapy applications to limit local side effects and targeted biological therapy or immunotherapy, including vaccines. Young age is a risk factor for distant metastasis within 6 mo following primary tumor resection. Neoadjuvant radiotherapy lasting 5-6 wk and surgical resection are indicated for high-grade STS (grade 2 or 3). Wide surgical excision alone may be acceptable for patients older than 70 years. However, locally advanced disease requires a multidisciplinary task of decision-making for amputation or limb salvage.

**Key Words:** Soft tissue sarcoma; Soft tissue tumors; Sarcomas; Oncology; Preoperative biopsy; Surgical management

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Pavlidis ET, Pavlidis TE. New trends in the surgical management of soft tissue sarcoma: The role of preoperative biopsy. *World J Clin Oncol* 2023; 14(2): 89-98

**URL**: https://www.wjgnet.com/2218-4333/full/v14/i2/89.htm

**DOI**: https://dx.doi.org/10.5306/wjco.v14.i2.89

**Core Tip:** The diagnosis and treatment of soft tissue sarcoma are multidisciplinary tasks, and wide surgical resection is an absolute necessity. Modern imaging, especially magnetic resonance imaging, is valuable, and preoperative core needle biopsy is the most indicated and effective diagnostic tool. Its correct planning affects surgical management because the opposite means dissemination of cancer cells into healthy anatomical structures influencing resectability and survival. New therapeutic modalities, including chemoradiation, biological agents and immunotherapy, can improve the outcomes of the main surgical management. In any case, the management policy is personalized.

**INTRODUCTION**

Soft tissue sarcomas (STSs) are rare tumors that originate from the mesenchyme (embryonic mesoderm) and affect children more often than adults[1]. They represent aggressive lesions accounting for approximately 1% of all adult malignancies and 7% of pediatric neoplasms[2,3]. Their incidence is calculated to affect 4-5 individuals *per* 100000 *per* year in Europe[4]; annually in the United States, there have been approximately 10000 new cases of soft tissue and bone sarcomas[5]. Likewise, in 2019, approximately 13000 new cases of ST and bone sarcomas were recognized in the United States with a main location (60%) in the limbs and trunk[6]. A French nationwide registry showed a continuing increase in incidence that is higher than reported and varies among different countries; however, the pathology evaluation should be made by sarcoma experts to avoid misdiagnosis which can occur in up to 30% of cases[7].

Limb STS has a rather better prognosis than retroperitoneal or pelvic STS. The most predominant pathologic type of STS is liposarcoma and leiomyosarcoma in adults and rhabdomyosarcoma in children[4]. Overall, 50 histopathologic subtypes with various cytogenetic profiles concerning soft tissue and bones have been recognized. The location in the vast majority concerns limbs, trunk, head and less often retro peritoneum and abdominal cavity[2]. These tumors mainly affect middle-aged adults but may be present at any age. Half of the patients have metastatic disease (first in the lungs and second in the liver) and intermediate-high grade STS at the time of diagnosis and require systemic therapy. The 5-year overall survival is approximately 55%[7-9].

Tumors above 3-5 cm in size, fast growing, deeply located, solid, cumbersome, possibly accompanied by palpable lymph nodes and causing or not causing pain must be suspected of potential malignancy. Then, an imaging evaluation [ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI)] is required and must precede biopsy[10]. Preoperative biopsy (percutaneous core needle, preferably) is a crucial diagnostic tool since there has been progress in planning multimodality management, which ensures improved outcomes[6,11]. The Ki-67 proliferation index has been proposed as a prognostic biomarker that, in addition to survival prediction, may determine the indication for lung or liver metastasectomy in carefully selected patients, improving the treatment[12].

Surgical intervention constitutes the cornerstone of management aiming at therapeutic wide excision with adequate margins[2]. Recurrence occurs in up to 50% of cases after surgery, mainly in the lungs[6]. Any effort must be made for limb salvage to avoid amputation. Neoadjuvant or adjuvant radiotherapy or chemotherapy has contributed to current progress[2]. Likewise, immunotherapy is a promising novel therapeutic option[1]. Young age is the only known risk factor for distant metastasis within 6 mo following curative resection[13]. Diabetes mellitus has a negative influence on the clinical outcome after therapeutic excision of STS[14].

Modern imaging, including positron emission tomography (PET)/CT and regular follow-up (every 3 mo for the first 3 years, every 6 mo for the following 2 years and then once every year for the next 10 years), nomograms and artificial intelligence for local recurrence or distant metastasis after surgery, have assisted further and improved the outcome[4,12].

In this narrative review, we highlight the current data on the diagnosis and treatment of STS, providing comprehensive, complete and modern knowledge to manage them.

**Diagnosis**

A thorough history, clinical examination and imaging are necessary requirements. Modern imaging techniques include US, CT, new MRI, and PET/CT. Imaging findings of limb STS correlate with the histopathologic findings[15]. According to the United Kingdom guidelines for the management of STS, any soft tissue lump more than 5 cm in size and, most importantly, increasing rapidly in size or painful must be considered malignant until assessed otherwise on imaging. Therefore, immediate US is mandatory. If the lesion seems to be benign, then the investigation will be terminated. Otherwise, a CT will follow and then MRI if it is indicated. When positive for malignancy or equivocal imaging findings exist, a preoperative biopsy will always be performed to confirm the diagnosis of STS[8], as described in detail below.

However, MRI is currently the method of choice. It provides accurate location, architecture, and vascularization of the tumor and determines the relationships with neighboring vital anatomic structures to plan the operative strategy and the extent of resection[16]. MRI findings may also distinguish low-grade from high-grade STS based on a diagnostic score (tumor heterogeneity, intratumoral and peritumoral enhancement). A score of 2 or 3 indicates a high-grade lesion, and a score of 0 or 1 indicates a low-grade lesion[16] . MRI radiomics and machine learning may accurately predict the tumor grade[17]. MRI is useful not only because it can guide preoperative biopsy[6] but also because high-grade sarcomas need neoadjuvant chemoradiation therapy[16]. It is known that preoperative biopsy may underassess the real grade of the definite complete specimen pathology due to the heterogeneity of STS[17]. Additionally, novel multiparametric MRI has provided promising results for the selection of patients who need neoadjuvant radiotherapy[9]. Preoperative imaging assessment of margin infiltration degree is essential for STS prognosis. MRI using the radiomics mode is a novel promising tool[18]. In addition, MRI using a deep learning radiomics nomogram can accurately predict preoperative lung metastases[19].

Preoperative imaging, pathologic subtypes and molecular findings are crucial. Mutations in the tumor suppressor genes, *i.e.*, the *Rb1* gene (retinoblastoma 1) and *TP53* gene (tumor protein 53) can exist[12]. Liquid biopsy by detecting genomic material in serum is a novel diagnostic, prognostic and staging tool. Genetic material mainly from blood but also from other body fluids (cerebrospinal fluid, saliva, urine, or feces) may be useful for the discovery of circulating tumor cells, cell-free DNA, exosomes, or metabolites[2]. These biomarkers provide valuable information regarding the tumor genetic profile and the status of the disease to ensure optimal monitoring and to identify the mechanisms implicating treatment resistance. The preliminary results are promising despite the technical difficulties, and liquid biopsy could replace invasive tissue biopsy in the future[20]. The heterogeneity of sarcomas poses further prognostic limitations. Furthermore, circulating tumor noncoding RNAs are promising biomarkers. However, all the above research efforts are in the preclinical stage for sarcomas[21]. In addition, the genomic profile may determine the adjuvant treatment choices[22].

For disease staging, the following imaging is necessary: (1) CT chest to detect lung metastases, since they are the most common metastatic involvement; and (2) CT abdomen to detect early hepatic or pelvic metastasis, particularly for the lower limb location of the primary focus to detect retroperitoneal lymph node involvement[4,8]. Based on relevant indications, the following imaging is recommended: (1) Whole-body scintigraphy for possible bone metastases; (2) CT or preferably MRI brain for possible metastases; (3) Whole-body MRI may be useful for occult metastases[8]; and (4) Likewise, for this reason, 18F-Fluoro-2-deoxyglucose PET/CT is currently more often in use[3]. However, it is absolutely indicated before making decisions for amputation or after postoperative recurrence[8]. After neoadjuvant radiation therapy, approximately 20% of patients with limb and trunk STS require a change in the management strategy because of distant lung metastases. The followed scheme includes a total dose of 50 Gy in 25 sessions of 2 Gy within a period of five weeks and then surgical intervention after an elapse of approximately ten weeks. Therefore, chest CT is reasonable for restaging after such a long time of 15 wk[23].

Histopathologic diagnosis is based on morphological, immunohistochemical and molecular pathologic features[10]. It should be made according to the latest World Health Organization classiﬁcation of soft tissue tumors. Liposarcoma, leiomyosarcoma, myxofibrosarcoma, pleomorphic undifferentiated sarcoma and synovial sarcoma constitute 75% of all STSs[15]. A second opinion of a pathologist expert may be valuable. There are three malignancy grades based on differentiation, necrosis and mitotic rate according to the Federation of the French Cancer Centres histological grading criteria for STS[8,10]. These parameters are scored 1 to 3 for differentiation and mitotic index and 0 to 2 for necrosis. A 3-grade system is obtained by summing the scores obtained for each of these 3 parameters, as shown in Table 1[8]. The Ki-67 proliferation index grading system may be useful for the evaluation of the histological grade of STS[24]. The staging of STS is based on the Tumor-Node-Metastasis classification system according to the American Joint Committee on Cancer 8th edition, asshown in Table 2[25].

**Preoperative biopsy**

Diagnosis and management of STS should be performed by experienced centers[26]. A preoperative biopsy is necessary to establish the diagnosis after the imaging evaluation. Imaging should be performed first to avoid any interference with the anatomical integrity of the region by the biopsy manipulations. The biopsy ensures diagnosis of histological type and staging, predicts the biological behavior of the tumor, indicates the need for preoperative (neoadjuvant) or even intraoperative radiation treatment, and neoadjuvant systemic chemotherapy, determines the best planning of the operative strategy and offers better patient information (reassuring) by weighing the risks and expectations[8,10,11,27]. A preoperative frozen section for immediate diagnosis is not recommended. It has no practical value since the regular review of a core needle biopsy (CNB) will safely establish the diagnosis[10].

The primary method of the first choice is CNB with needles of 14-18 gauges. Several needle samples (4-10) are required to increase the maximum chance of a correct diagnosis[6,8,10,28]. It was performed under imaging guidance (US, CT) and achieved adequate specimens for complete histopathologic evaluation along with immunohistochemical assays. Most cases are performed under local anesthesia, but sedation may be required in some cases. The complications (hemorrhage or infection) are minimal[11]. A large series from Royal Marsden Hospital United Kingdom including 530 cases of CNB performed under local anesthesia showed that it was diagnostic in 93% of cases, needed to be repeated in 7% of cases, had a complication rate of 0.4%, had a diagnostic accuracy rate of 97.6% in distinguishing STS from benign lesions (sensitivity of 96.3%, speciﬁcity of 99.4%, positive predictive value of 99.5%, negative predictive value of 95.1%) and had a grade accuracy rate of 86.3%[29]. Adequate tissue samples must be obtained in different directions within the tumor through a single skin incision; to avoid rare needle tract recurrence, the selection of the biopsy site should be planned so that it is included in the subsequent resection, if required[29].

Preoperative CT-guided CNB is accurate and valuable for intraabdominal and retroperitoneal sarcomas[30]. A recent study from the United States based on the National Cancer Database including 2620 patients who underwent surgery for nonmetastatic retroperitoneal sarcoma showed that preoperative biopsy (performed in 42.4% of cases) was proven useful with better outcomes and improved survival[31].

Fine needle aspiration does not provide tissue samples and offers cytologic rather than histologic information. Its utility is limited only to recurrence cases of an already known STS[11]. Open biopsy techniques include incisional biopsy by removing a small part of the tumor. It is associated with a 2% possibility of complications (inflammation, hematoma) but most importantly dissemination of malignant cells and delay in the treatment. Its rare indication is limited to failure of CNB. Excisional biopsy by whole tumor removal does not have any place in suspected STS but only in superficial small soft tissue tumors (less than 2 cm in size), which have minimal malignant potential. The basic principles of open biopsy are meticulous hemostasis and avoidance of drain placement[8,11].

**Management**

The management of abdominal STS at an experienced center with a multidisciplinary approach provides improved outcomes and better prognosis[32]. The initial referral, even based on suspicion, to such a center is of great importance to ensure the optimal chance in accurate diagnosis and proper management[22]. Surgery is the standard treatment and must be performed by an experienced surgeon. Wide excision with adequate margins at least 1 cm or even 2 cm, free of involvement, constitutes the operative target to achieve a residual zero (R0) resection[2,33-35]. However, vital neighboring anatomical structures may sometimes restrict the resection margin, and microscopic infiltration may be found within it (R1 resection). Further treatment is needed for positive resection margins to restrict recurrence[36]. It has been reported that high-grade tumors have a negative effect on overall survival, but resection margins do not. The 5-year overall survival was 71.1% for R0 resection and 70.2% for R1 resection[37]. Lymph node metastases are rare in STS, and sentinel lymph node biopsy and lymphadenectomy are limited and debatable[38]. Neoadjuvant radiotherapy and wide excision have been widely used but are associated with wound complications[39], reaching up to 39%[40]. This rate is limited to half at experienced centers[40]. Neoadjuvant radiotherapy tends to replace adjuvant radiotherapy and is strongly recommended[41,42]. Concurrent neoadjuvant chemoradiation therapy increases the chance of R0 resection[43]. For high-grade deep tumors, T2 or more (stage II or III), wide excision and adjuvant radiation therapy (external beam 60-76 Gy) for local control is the indicated policy[2,10,44,45]. Limb sparing surgery combined with radiotherapy is the current preferable method for such tumors of limbs[46]. It must precede preoperative traditional fractioned radiotherapy of 50-50.4 Gy with a daily dose of 1.8-2 Gy over 5-6 wk[47-49]. Generally, a daily dose > 2.2 Gy is usually hypofractionated radiotherapy[47]. Novel techniques for radiotherapy, including intensity-modulated radiation therapy, proton beam therapy, intraoperative electron radiotherapy and postoperative brachytherapy (*via* catheters in the surgical field), promise to decrease the side effects of standard radiotherapy while achieving better local control[2,8,10,50].

Chemotherapy with doxorubicin alone or in combination with ifosfamide is the basic scheme as a neo-adjuvant or adjuvant[2]. However, there have been conflicting aspects for adjuvant chemotherapy after R0 resection[51]. Tyrosine-kinase inhibitors (pazopanib, sunitinib, imatinib) have been indicated in some specific types[2]. In advanced metastatic cases, gemcitabine has been used in combination with docetaxel, vinorelbine, or dacarbazine, but with limited results[2]. Isolated hyperthermic limb perfusion (IHLP) with tumor necrosis factor-alpha and melphalan is another proposed option for limb STS[2,52]. A recent nationwide multicenter study from the Netherlands showed that in unresectable limb STS, preoperative IHLP or neoadjuvant radiotherapy avoided both amputations with acceptable oncological outcomes[53]. Wide surgical excision alone without neoadjuvant or adjuvant chemotherapy may be acceptable for patients over 70 years of age, providing comparable survival[54]. Frail very elderly patients (more than 80 years old) can tolerate an operative intervention for limb STS well[55,56].

Overall, unplanned excisions were 18.2% among 2187 primary operations for STS in the Netherlands Cancer Registry database[57]. It is known that unplanned surgical excision is related to an increased risk of local recurrence despite any adjuvant oncologic therapy[58]. For this reason, reresection is an option after positive or uncertain resection margins, but it is associated with increased morbidity and residual disease, which requires complete information for the patient[59]. However, a recent large study from Japan including 4483 operations (4128 planned excisions and 355 unplanned excisions) for limb STS showed that additional excision after unplanned excision was not associated with increased mortality and local recurrence compared to planned excision[60]. Furthermore, in the case of R1 or even R2 resection, reresection in combination with perioperative radiotherapy must be considered[61]. Surgical resection of lung metastases has improved overall survival (49 mo median and 42% 5-year). However, R1 resection of the primary tumor and ≥ 2 metastases decrease it[62]. Pulmonary metastasectomy improves the prognosis compared to conservative treatment[63].

The comprehensive assessment of recurrence risk has led to an increasing number of personalized management tools[64], including surgical operation, radiotherapy, novel promising targeted biological agents and immunotherapy (monoclonal antibodies, cellular therapies with modified T cells and natural killer cells, or vaccines)[1,2,12,65,66]. For retroperitoneal STS, aggressive surgical management has been recommended, since it showed satisfactory results for primary tumors but not for recurrence[67-70]. Likewise, for abdominal STS, surgery is the standard treatment[71]. Operative intervention and radiotherapy maximize local control[72]. For abdominal wall STS, extensive surgery is indicated for local control despite the rate but acceptability of incisional hernia[73]. For metastatic STS, systemic therapy and local control by surgical resection, usually or recently by stereotactic body radiation therapy, have been recommended[74]. MRI-guided radiotherapy is another recent alternative modality[75]. For advanced retroperitoneal liposarcoma, the most common subtype of retroperitoneal STS, treatment based on targetable molecular pathways may be the future perspective[76].

A recent systematic review showed that patients with hepatic, abdominal or retroperitoneal metastasis undergoing metastasectomy have a survival benefit for a long period of time compared with those undergoing chemotherapy[4]. A multicenter retrospective cohort study from the United States using the National Cancer Database including 8953 cases showed that younger adult patients under 40 years old had a notable proportion (14.3%) of limb STS and more challenging management. They received chemotherapy more often than radiotherapy *vs* older patients[77]. A study including 1124 patients with distant metastases at diagnosis, stage IV STS, from the United States National Cancer Database showed that metastasectomy after resection of the primary site increased survival[78]. In any case, regardless of the subsequent kind of metastasis management, primary tumor resection is necessary to improve survival[79].

Visceral obesity is common in retroperitoneal and trunk sarcoma, and it has a negative effect on surgical results but not on oncologic outcomes[80]. A recent international multicenter study using clinical data as prognostic factors of 493 patients with STS found that increased modified Glasgow prognostic score (used in various malignancies and based on preoperative C-reactive protein and albumin levels to calculate a score from 0 to 2), tumor size, grade, neutrophil/lymphocyte ratio, and recurrence were associated with reduced survival[81]. Likewise, another study found a predictive effect on survival of retroperitoneal STSusing body mass index, total protein serum levels and blood white cell count by performing prognostic models[82].

The 5-year survival for limb and trunk STS was found to be 71.6% in local recurrence-free patients, 75.7% in metastasis-free and 84.7% in disease-specific[83]. The 3-year overall survival for head and neck STS was 68%, for disease specific 71% and recurrence free 61%. Higher tumor grade and tumor size greater than 5 cm were associated with reduced disease-specific survival[26].

**CONCLUSION**

Any suspected soft tissue lump above 5 cm in size must be investigated thoroughly, first by US and CT. For further detailed information, if needed, modern MRI prevails among the imaging modalities and constitutes the method of the first option. Preoperative CNB, always after imaging, is essential in confirming the diagnosis and determining the staging with prognosis and the optimal planning of the management policy. Liquid biopsy and genomic profiling will likely be useful in diagnosis, prognosis and treatment. A multidisciplinary approach is valuable and mandatory. Wide surgical excision with an acceptable healthy margin of 1 cm is the method of choice in management. In locally borderline tumors affecting limb vessels or nerves, modern neoadjuvant or adjuvant chemoradiation therapy may ensure limb savings by downstaging the tumor, thus avoiding amputation. Additionally, this therapy in the advanced metastatic stage improves surgical outcomes after mandatory primary tumor excision. Novel targeted biological agents and immunotherapy may contribute further. Detailed follow-up for a long time is recommended because of the outstanding possibility of recurrence, in which the chance of reresection or stereotactic radiotherapy exists. However, in any case, the management of STS should be personalized and performed by an expert team.

**REFERENCES**

1 **Ghosn M**, El Rassy E, Kourie HR. Immunotherapies in sarcoma: Updates and future perspectives. *World J Clin Oncol* 2017; **8**: 145-150 [PMID: 28439495 DOI: 10.5306/wjco.v8.i2.145]

2 **Gómez J**, Tsagozis P. Multidisciplinary treatment of soft tissue sarcomas: An update. *World J Clin Oncol* 2020; **11**: 180-189 [PMID: 32355640 DOI: 10.5306/wjco.v11.i4.180]

3 **Benz MR**, Crompton JG, Harder D. PET/CT Variants and Pitfalls in Bone and Soft Tissue Sarcoma. *Semin Nucl Med* 2021; **51**: 584-592 [PMID: 34238508 DOI: 10.1053/j.semnuclmed.2021.06.009]

4 **Smolle MA**, Leithner A, Bernhardt GA. Abdominal metastases of primary extremity soft tissue sarcoma: A systematic review. *World J Clin Oncol* 2020; **11**: 74-82 [PMID: 32133276 DOI: 10.5306/wjco.v11.i2.74]

5 **Blank AT**, Larson BM, Shaw S, Wakefield CJ, King T, Jones KB, Randall RL. National Comprehensive Cancer Network guidelines compliance of a sarcoma service: A retrospective review. *World J Clin Oncol* 2020; **11**: 389-396 [PMID: 32874952 DOI: 10.5306/wjco.v11.i6.389]

6 **Roland CL**. Soft Tissue Tumors of the Extremity. *Surg Clin North Am* 2020; **100**: 669-680 [PMID: 32402308 DOI: 10.1016/j.suc.2020.02.015]

7 **de Pinieux G**, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, Mishellany F, Charon-Barra C, Croce S, Doucet L, Quintin-Rouet I, Chateau MC, Bazille C, Valo I, Chetaille B, Ortonne N, Brouchet A, Rochaix P, Demuret A, Ghnassia JP, Mescam L, Macagno N, Birtwisle-Peyrottes I, Delfour C, Angot E, Pommepuy I, Ranchere D, Chemin-Airiau C, Jean-Denis M, Fayet Y, Courrèges JB, Mesli N, Berchoud J, Toulmonde M, Italiano A, Le Cesne A, Penel N, Ducimetiere F, Gouin F, Coindre JM, Blay JY; NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. *PLoS One* 2021; **16**: e0246958 [PMID: 33630918 DOI: 10.1371/journal.pone.0246958]

8 **Dangoor A**, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. *Clin Sarcoma Res* 2016; **6**: 20 [PMID: 27891213 DOI: 10.1186/s13569-016-0060-4]

9 **Kershaw L**, Forker L, Roberts D, Sanderson B, Shenjere P, Wylie J, Coyle C, Kochhar R, Manoharan P, Choudhury A. Feasibility of a multiparametric MRI protocol for imaging biomarkers associated with neoadjuvant radiotherapy for soft tissue sarcoma. *BJR Open* 2021; **3**: 20200061 [PMID: 35707756 DOI: 10.1259/bjro.20200061]

10 **Casali PG**, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; **21 Suppl 5**: v198-v203 [PMID: 20555081 DOI: 10.1093/annonc/mdq209]

11 **Tuttle R**, Kane JM 3rd. Biopsy techniques for soft tissue and bowel sarcomas. *J Surg Oncol* 2015; **111**: 504-512 [PMID: 25663366 DOI: 10.1002/jso.23870]

12 **Brennan MF**, Singer S. Five decades of sarcoma care at Memorial Sloan Kettering Cancer Center. *J Surg Oncol* 2022; **126**: 896-901 [PMID: 36087086 DOI: 10.1002/jso.27032]

13 **Tsuchie H**, Emori M, Nagasawa H, Murahashi Y, Mizushima E, Shimizu J, Yamashita T, Miyakoshi N. Risk Factors of Early Distant Metastasis After Primary Tumor Treatment in Soft Tissue Sarcoma. *In Vivo* 2022; **36**: 2260-2264 [PMID: 36099122 DOI: 10.21873/invivo.12954]

14 **Stelzl A**, Aziz F, Riedl JM, Posch F, Smolle MA, Stojakovic T, Terbuch A, Pichler M, Bergovec M, Leithner A, Liegl-Atzwanger B, Stotz M, Gerger A, Sourij H, Szkandera J. Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients. *Sci Rep* 2020; **10**: 12438 [PMID: 32709908 DOI: 10.1038/s41598-020-69237-y]

15 **Ramakrishnan K**, Levy N, Goldbach A, Nagarathinam R, Ali S, Ling S, Jonnalagadda P. Imaging of soft tissue sarcomas of the extremities with radiologic-pathologic correlation. *Curr Probl Diagn Radiol* 2022; **51**: 868-877 [PMID: 35654634 DOI: 10.1067/j.cpradiol.2022.04.005]

16 **Boudabbous S**, Hamard M, Saiji E, Gorican K, Poletti PA, Becker M, Neroladaki A. What morphological MRI features enable differentiation of low-grade from high-grade soft tissue sarcoma? *BJR Open* 2022; **4**: 20210081 [PMID: 36105415 DOI: 10.1259/bjro.20210081]

17 **Xu W**, Hao D, Hou F, Zhang D, Wang H. Soft Tissue Sarcoma: Preoperative MRI-Based Radiomics and Machine Learning May Be Accurate Predictors of Histopathologic Grade. *AJR Am J Roentgenol* 2020; **215**: 963-969 [PMID: 32755226 DOI: 10.2214/AJR.19.22147]

18 **Lee S**, Jung JY, Nam Y, Jung CK, Lee SY, Lee J, Shin SH, Chung YG. Diagnosis of Marginal Infiltration in Soft Tissue Sarcoma by Radiomics Approach Using T2-Weighted Dixon Sequence. *J Magn Reson Imaging* 2022 [PMID: 35808915 DOI: 10.1002/jmri.28331]

19 **Liang HY**, Yang SF, Zou HM, Hou F, Duan LS, Huang CC, Xu JX, Liu SL, Hao DP, Wang HX. Deep Learning Radiomics Nomogram to Predict Lung Metastasis in Soft-Tissue Sarcoma: A Multi-Center Study. *Front Oncol* 2022; **12**: 897676 [PMID: 35814362 DOI: 10.3389/fonc.2022.897676]

20 **van der Laan P**, van Houdt WJ, van den Broek D, Steeghs N, van der Graaf WTA. Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand? *Biomedicines* 2021; **9** [PMID: 34680432 DOI: 10.3390/biomedicines9101315]

21 **Wei J**, Liu X, Li T, Xing P, Zhang C, Yang J. The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids. *J Cancer* 2020; **11**: 5293-5308 [PMID: 32742476 DOI: 10.7150/jca.42816]

22 **Kirchberg J**, Blum SFU, Pablik J, Herold S, Hoffmann RT, Baretton G, Weitz J. [Preoperative diagnostics and typing of abdominal soft tissue sarcomas]. *Chirurg* 2022; **93**: 5-15 [PMID: 34757436 DOI: 10.1007/s00104-021-01528-0]

23 **Acem I**, Schultze BTA, Schoonbeek A, van Houdt WJ, van de Sande MAJ, Visser JJ, Grünhagen DJ, Verhoef C. The added value of chest imaging after neoadjuvant radiotherapy for soft tissue sarcoma of the extremities and trunk wall: A retrospective cohort study. *Eur J Surg Oncol* 2022; **48**: 1543-1549 [PMID: 35393169 DOI: 10.1016/j.ejso.2022.03.231]

24 **Tanaka K**, Hasegawa T, Nojima T, Oda Y, Mizusawa J, Fukuda H, Iwamoto Y. Prospective evaluation of Ki-67 system in histological grading of soft tissue sarcomas in the Japan Clinical Oncology Group Study JCOG0304. *World J Surg Oncol* 2016; **14**: 110 [PMID: 27091124 DOI: 10.1186/s12957-016-0869-6]

25 **Cates JMM**. The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database. *J Natl Compr Canc Netw* 2018; **16**: 144-152 [PMID: 29439175 DOI: 10.6004/jnccn.2017.7042]

26 **Roos JH**, Mäkitie AA, Tarkkanen J, Ilmarinen TT. Pretreatment tumor sampling and prognostic factors in patients with soft-tissue sarcoma of the head and neck. *Eur Arch Otorhinolaryngol* 2022; **279**: 3147-3155 [PMID: 34773167 DOI: 10.1007/s00405-021-07162-0]

27 **MacGillis KJ**, Heaberlin J, Mejia A. Clinical Decision Making for a Soft Tissue Hand Mass: When and How to Biopsy. *J Hand Surg Am* 2018; **43**: 1123-1129 [PMID: 29908925 DOI: 10.1016/j.jhsa.2018.03.032]

28 **Young R**, Snow H, Hendry S, Mitchell C, Slavin J, Schlicht S, Na L, Hofman MS, Gyorki DE. Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study. *ANZ J Surg* 2020; **90**: 497-502 [PMID: 32064728 DOI: 10.1111/ans.15723]

29 **Strauss DC**, Qureshi YA, Hayes AJ, Thway K, Fisher C, Thomas JM. The role of core needle biopsy in the diagnosis of suspected soft tissue tumours. *J Surg Oncol* 2010; **102**: 523-529 [PMID: 20872955 DOI: 10.1002/jso.21600]

30 **Luca Alatzides G**, Luisa Steinberg H, Schildhaus HU, Hamacher R, Kaths M, Grueneisen J, Treckmann J, Bauer S, Umutlu L, Schaarschmidt B. Is preoperative CT-guided biopsy a valuable tool in the diagnostic workup of patients with visceral and retroperitoneal sarcoma? *Eur J Radiol* 2022; **155**: 110470 [PMID: 35985092 DOI: 10.1016/j.ejrad.2022.110470]

31 **Straker RJ 3rd**, Song Y, Shannon AB, Marcinak CT, Miura JT, Fraker DL, Karakousis GC. Preoperative Biopsy in Patients with Retroperitoneal Sarcoma: Usage and Outcomes in a National Cohort. *Ann Surg Oncol* 2021; **28**: 6868-6879 [PMID: 33591480 DOI: 10.1245/s10434-021-09691-8]

32 **Acem I**, Smit MM, Verhoef C, van Houdt WJ, Haas RL, van der Hage JA, Grünhagen DJ, van de Sande MAJ. Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent. *Ann Surg Oncol* 2021; **28**: 7923-7936 [PMID: 33970372 DOI: 10.1245/s10434-021-09946-4]

33 **Patel A**, Kane JM 3rd. Wide Resection of Extremity/Truncal Soft Tissue Sarcomas. *Surg Clin North Am* 2022; **102**: 551-565 [PMID: 35952687 DOI: 10.1016/j.suc.2022.05.002]

34 **Kheiran A**, Eastley NC, Hanson JR, McCulloch TA, Allen PE, Ashford RU. The importance of the early appropriate management of foot and ankle soft tissue sarcomas - experiences of a regional sarcoma service. *Foot (Edinb)* 2022; **50**: 101866 [PMID: 35219135 DOI: 10.1016/j.foot.2021.101866]

35 **Gronchi A**. Surgery in soft tissue sarcoma: the thin line between a surgical or more conservative approach. *Future Oncol* 2021; **17**: 3-6 [PMID: 34107729 DOI: 10.2217/fon-2021-0449]

36 **Matheron G**, Ardakani A, Nasir A, Gikas P. Positive Margins Following Excision of Primary Bone & Soft Tissue Tumours in a Tertiary Centre and the Impact on Patient Outcomes. *Cureus* 2022; **14**: e21235 [PMID: 35186531 DOI: 10.7759/cureus.21235]

37 **Shafiq MB Sr**, Rafi I, Shoaib A, Ali S, Iqbal F, Latif T, Mushtaq U. The Outcome of Extremity Soft Tissue Sarcomas in Terms of Resection Margins: A Study From a Cancer Dedicated Center. *Cureus* 2022; **14**: e26086 [PMID: 35875266 DOI: 10.7759/cureus.26086]

38 **Witt RG**, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. *Ann Surg Oncol* 2022; **29**: 7092-7100 [PMID: 35501583 DOI: 10.1245/s10434-022-11803-x]

39 **Kungwengwe G**, Clancy R, Vass J, Slade R, Sandhar S, Dobbs TD, Bragg TWH. Preoperative versus Post-operative Radiotherapy for Extremity Soft tissue Sarcoma: a Systematic Review and Meta-analysis of Long-term Survival. *J Plast Reconstr Aesthet Surg* 2021; **74**: 2443-2457 [PMID: 34266806 DOI: 10.1016/j.bjps.2021.05.043]

40 **Ellison C**, King DM, Neilson JC, Wooldridge A, Charlson JA, Hackbarth DA, Johnstone C, Bedi M. Preoperative Radiation Performed at a Nonsarcoma Center May Lead to Increased Wound Complications Following Resection in Patients With Soft Tissue Sarcomas. *Am J Clin Oncol* 2021; **44**: 619-623 [PMID: 34753886 DOI: 10.1097/COC.0000000000000870]

41 **Van Meekeren M**, Fiocco M, Ho VKY, Bovée JVMG, Gelderblom H, Haas RL. Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database Analysis. *Sarcoma* 2021; **2021**: 9976122 [PMID: 34335076 DOI: 10.1155/2021/9976122]

42 **Salerno KE**, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, Chung P, DeLaney TF, Folpe A, Kane JM, Li XA, Petersen I, Powell J, Stolten M, Thorpe S, Trent JC, Voermans M, Guadagnolo BA. Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol* 2021; **11**: 339-351 [PMID: 34326023 DOI: 10.1016/j.prro.2021.04.005]

43 **Attal J**, Cabarrou B, Valentin T, Nesseler JP, Stoeckle E, Ducassou A, Filleron T, Le Guellec S, Boulet B, Vogin G, Ferron G, Moyal EC, Delannes M, Chevreau C. Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment. *Strahlenther Onkol* 2021; **197**: 1051-1062 [PMID: 34673991 DOI: 10.1007/s00066-021-01847-5]

44 **Lawrenz JM**, Johnson SR, Zhu K, McKeon M, Moran CP, Vega J, Hajdu KS, Norris JP, Luo LY, Shinohara ET, Cates JMM, Rubin BP, Reith JD, Halpern JL, Mesko NW, Schwartz HS, Nystrom LM, Holt GE. Adjuvant Radiation after Primary Resection of Atypical Lipomatous Tumors of the Extremity Reduces Local Recurrence but Increases Complications: A Multicenter Evaluation. *Sarcoma* 2022; **2022**: 2091677 [PMID: 36046749 DOI: 10.1155/2022/2091677]

45 **Levy A**, Honoré C, Dumont S, Bourdais R, Cavalcanti A, Faron M, Ngo C, Haddag-Miliani L, Le Cesne A, Mir O, Le Péchoux C. [Preoperative versus postoperative radiotherapy in soft tissue sarcomas: State of the art and perspectives]. *Bull Cancer* 2021; **108**: 868-876 [PMID: 34246458 DOI: 10.1016/j.bulcan.2021.03.012]

46 **Cammelli S**, Cortesi A, Buwenge M, Zamagni A, Ferioli M, Ghigi G, Romeo A, Morganti AG. The role of radiotherapy in adult soft tissues sarcoma of the extremities. *Eur J Orthop Surg Traumatol* 2021; **31**: 1583-1596 [PMID: 33954820 DOI: 10.1007/s00590-021-02990-6]

47 **Roohani S**, Ehret F, Kobus M, Flörcken A, Märdian S, Striefler JK, Rau D, Öllinger R, Jarosch A, Budach V, Kaul D. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review. *Radiat Oncol* 2022; **17**: 159 [PMID: 36104789 DOI: 10.1186/s13014-022-02072-9]

48 **Kaiser D**, Schelm M, Gerber C, Brown ML, Müller DA. The effect of preoperative radiotherapy on surgical resectability, tumor volume and the necrosis rate of soft tissue sarcomas: A retrospective single-center analysis. *Surg Oncol* 2021; **39**: 101668 [PMID: 34653769 DOI: 10.1016/j.suronc.2021.101668]

49 **Dei Tos AP**, Bonvalot S, Haas R. Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy. *Expert Rev Anticancer Ther* 2020; **20**: 3-13 [PMID: 32293209 DOI: 10.1080/14737140.2020.1753509]

50 **Laughlin BS**, Golafshar MA, Ahmed S, Prince M, Anderson JD, Vern-Gross T, Seetharam M, Goulding K, Petersen I, DeWees T, Ashman JB. Early Experience Using Proton Beam Therapy for Extremity Soft Tissue Sarcoma: A Multicenter Study. *Int J Part Ther* 2022; **9**: 1-11 [PMID: 35774491 DOI: 10.14338/IJPT-21-00037.1]

51 **Eraslan E**, Ilhan Gulesen A, Yildiz F, Tufan G, Yalcintas Arslan U, Alkis N. The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience. *J BUON* 2021; **26**: 2169-2175 [PMID: 34761631]

52 **Lindner LH**, Blay JY, Eggermont AMM, Issels RD. Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. *Eur J Cancer* 2021; **147**: 164-169 [PMID: 33684876 DOI: 10.1016/j.ejca.2021.02.002]

53 **van Praag VM**, Fiocco M, Bleckman RF, van Houdt WJ, Haas RLM, Verhoef C, Grunhagen DJ, van Ginkel RJ, Bonenkamp JJ, van de Sande MAJ. The oncological outcomes of isolated limb perfusion and neo-adjuvant radiotherapy in soft tissue sarcoma patients - A nationwide multicenter study. *Eur J Surg Oncol* 2022 [PMID: 36085118 DOI: 10.1016/j.ejso.2022.08.018]

54 **Aoki Y**, Tome Y, Oshiro H, Katsuki R, Tamaki T, Wada N, Karube K, Nishida K. Wide excision alone for elderly patients aged > 70 years old with soft tissue sarcomas. *Medicine (Baltimore)* 2022; **101**: e30127 [PMID: 36086737 DOI: 10.1097/MD.0000000000030127]

55 **Sivarajah G**, Davies E, Hurley A, Strauss DC, Smith MJF, Hayes AJ. Frailty in Very Elderly Patients is Not Associated with Adverse Surgical or Oncological Outcomes in Extremity Surgery for Soft Tissue Sarcoma. *Ann Surg Oncol* 2022; **29**: 3982-3990 [PMID: 35118523 DOI: 10.1245/s10434-021-11292-4]

56 **Hartley LJ**, AlAqeel M, Kurisunkal VJ, Evans S. Outcomes of soft-tissue sarcoma in nonagenarians. *Bone Joint J* 2022; **104-B**: 177-182 [PMID: 34969278 DOI: 10.1302/0301-620X.104B1.BJJ-2021-0761.R1]

57 **Melis AS**, Vos M, Schuurman MS, van Dalen T, van Houdt WJ, van der Hage JA, Schrage YM, Been LB, Bonenkamp JB, Bemelmans MHA, Grünhagen DJ, Verhoef C, Ho VKY; Dutch Sarcoma Group (DSG). Incidence of unplanned excisions of soft tissue sarcomas in the Netherlands: A population-based study. *Eur J Surg Oncol* 2022; **48**: 994-1000 [PMID: 34848102 DOI: 10.1016/j.ejso.2021.11.123]

58 **Grignol VP**, Lopez-Aguiar AG. The Implications of an Unplanned Sarcoma Excision (the "Whoops" Operation). *Surg Clin North Am* 2022; **102**: 529-538 [PMID: 35952685 DOI: 10.1016/j.suc.2022.04.002]

59 **Traweek RS**, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. *Ann Surg Oncol* 2023; **30**: 480-489 [PMID: 36085392 DOI: 10.1245/s10434-022-12359-6]

60 **Nakamura T**, Kawai A, Hagi T, Asanuma K, Sudo A. A comparison of clinical outcomes between additional excision after unplanned and planned excisions in patients with soft-tissue sarcoma of the limb : a propensity matching cohort study. *Bone Joint J* 2021; **103-B**: 1809-1814 [PMID: 34847719 DOI: 10.1302/0301-620X.103B12.BJJ-2021-0037.R1]

61 **Le Péchoux C**, Llacer C, Sargos P, Moureau-Zabotto L, Ducassou A, Sunyach MP, Biston MC, Thariat J. Conformal radiotherapy in management of soft tissue sarcoma in adults. *Cancer Radiother* 2022; **26**: 377-387 [PMID: 34961656 DOI: 10.1016/j.canrad.2021.11.023]

62 **Lee RM**, Ethun CG, Gamboa AC, Turgeon MK, Tran T, Poultsides G, Grignol V, Bedi M, Mogal H, Clarke CN, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Oskouei SV, Monson DK, Reimer NB, Maithel SK, Pickens A, Cardona K. A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. *J Surg Oncol* 2021; **124**: 1477-1484 [PMID: 34374088 DOI: 10.1002/jso.26635]

63 **Gusho CA**, Seder CW, Lopez-Hisijos N, Blank AT, Batus M. Pulmonary metastasectomy in bone and soft tissue sarcoma with metastasis to the lung. *Interact Cardiovasc Thorac Surg* 2021; **33**: 879-884 [PMID: 34516633 DOI: 10.1093/icvts/ivab178]

64 **Acem I**, van de Sande MAJ. Prediction tools for the personalized management of soft-tissue sarcomas of the extremity. *Bone Joint J* 2022; **104-B**: 1011-1016 [PMID: 36047022 DOI: 10.1302/0301-620X.104B9.BJJ-2022-0647]

65 **Banks LB**, D'Angelo SP. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. *J Natl Compr Canc Netw* 2022; **20**: 834-844 [PMID: 35830892 DOI: 10.6004/jnccn.2022.7027]

66 **Yuan J**, Li X, Yu S. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma. *Cancer Control* 2021; **28**: 10732748211038424 [PMID: 34844463 DOI: 10.1177/10732748211038424]

67 **Lv A**, Li Y, Li ZW, Mao LL, Tian XY, Hao CY. Treatment algorithm and surgical outcome for primary and recurrent retroperitoneal sarcomas: A long-term single-center experience of 242 cases. *J Surg Oncol* 2022; **126**: 1288-1298 [PMID: 35943840 DOI: 10.1002/jso.27040]

68 **Siew CCH**, Cardona K, van Houdt WJ. Management of recurrent retroperitoneal sarcomas. *Eur J Surg Oncol* 2022 [PMID: 35810040 DOI: 10.1016/j.ejso.2022.06.008]

69 **Danieli M**, Swallow CJ, Gronchi A. How to treat liposarcomas located in retroperitoneum. *Eur J Surg Oncol* 2022 [PMID: 35623985 DOI: 10.1016/j.ejso.2022.04.020]

70 **Willis F**, Schneider M. [Retroperitoneal soft tissue sarcoma: surgical management]. *Chirurg* 2022; **93**: 16-26 [PMID: 34596706 DOI: 10.1007/s00104-021-01506-6]

71 **Djafarrian R**, Zingg T, Digklia A, Becce F, Özsahin EM, La Rosa S, Demartines N, Matter M. [Management of abdominal soft tissue sarcomas]. *Rev Med Suisse* 2021; **17**: 1172-1176 [PMID: 34133095]

72 **Rust DJ**, Kato T, Yoon SS. Treatment for local control of retroperitoneal and pelvis sarcomas: A review of the literature. *Surg Oncol* 2022; **43**: 101814 [PMID: 35834940 DOI: 10.1016/j.suronc.2022.101814]

73 **Neuberg M**, Mir O, Levy A, Sourrouille I, Dumont S, Haddag-Miliani L, Ngo C, Mihoubi F, Rimareix F, Le Péchoux C, Adam J, Honart JF, Ceribelli C, Le Cesne A, Leymarie N, Faron M, Honoré C. Surgical management of soft tissue tumors of the abdominal wall: A retrospective study in a high-volume sarcoma center. *J Surg Oncol* 2021; **124**: 679-686 [PMID: 34120344 DOI: 10.1002/jso.26566]

74 **Gutkin PM**, von Eyben R, Chin A, Donaldson SS, Oh J, Jiang A, Ganjoo KN, Avedian RS, Bruzoni M, Steffner RJ, Moding EJ, Hiniker SM. Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma. *Int J Radiat Oncol Biol Phys* 2022; **114**: 771-779 [PMID: 35643255 DOI: 10.1016/j.ijrobp.2022.05.017]

75 **Blitzer GC**, Yadav P, Morris ZS. The Role of MRI-Guided Radiotherapy for Soft Tissue Sarcomas. *J Clin Med* 2022; **11** [PMID: 35207317 DOI: 10.3390/jcm11041042]

76 **Casadei L**, de Faria FCC, Lopez-Aguiar A, Pollock RE, Grignol V. Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma. *Cancers (Basel)* 2022; **14** [PMID: 35326514 DOI: 10.3390/cancers14061362]

77 **Seldon C**, Shrivastava G, Al-Awady A, Asher D, Ramey S, Fernandez M, Dooley S, Kwon D, Zhao W, Goel N, Diwanji T, Subhawong T, Trent J, Yechieli R. Variation in Management of Extremity Soft-Tissue Sarcoma in Younger vs Older Adults. *JAMA Netw Open* 2021; **4**: e2120951 [PMID: 34415314 DOI: 10.1001/jamanetworkopen.2021.20951]

78 **Abugideiri M**, Janopaul-Naylor J, Switchenko J, Tian S, Read W, Press R, Oskouei S, Reimer N, Ferris M, Cassidy RJ, Behera M, Monson D, Landry J, Godette KD, Patel PR. Impact of Metastasectomy and Aggressive Local Therapy in Newly Diagnosed Metastatic Soft Tissue Sarcoma: An Analysis of the NCDB. *Ann Surg Oncol* 2022; **29**: 649-659 [PMID: 34272614 DOI: 10.1245/s10434-021-10466-4]

79 **Matsuoka M**, Onodera T, Yokota I, Iwasaki K, Matsubara S, Hishimura R, Kondo E, Iwasaki N. Surgical resection of primary tumor in the extremities improves survival for metastatic soft-tissue sarcoma patients: a population-based study of the SEER database. *Clin Transl Oncol* 2021; **23**: 2474-2481 [PMID: 34060011 DOI: 10.1007/s12094-021-02646-1]

80 **Boyle EA**, Elliott JA, McIntyre TV, Barnes ME, Donlon NE, Umair M, Gillis AE, Ridgway PF. Body composition is associated with operative and oncologic outcomes in the management of retroperitoneal and trunk soft tissue sarcoma. *Am J Surg* 2022; **223**: 729-737 [PMID: 34389158 DOI: 10.1016/j.amjsurg.2021.08.005]

81 **Spence S**, Doonan J, Farhan-Alanie OM, Chan CD, Tong D, Cho HS, Sahu MA, Traub F, Gupta S; The MPGS Study Group. Does the modified Glasgow Prognostic Score aid in the management of patients undergoing surgery for a soft-tissue sarcoma? : an international multicentre study. *Bone Joint J* 2022; **104-B**: 168-176 [PMID: 34969280 DOI: 10.1302/0301-620X.104B1.BJJ-2021-0874.R1]

82 **Yao Y**, Wang Z, Yong L, Yao Q, Tian X, Wang T, Yang Q, Hao C, Zhou T. Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma. *CPT Pharmacometrics Syst Pharmacol* 2022; **11**: 1170-1182 [PMID: 35758865 DOI: 10.1002/psp4.12835]

83 **Morii T**, Anazawa U, Sato C, Iwata S, Nakagawa M, Endo M, Nakamura T, Ikuta K, Nishida Y, Nakayama R, Udaka T, Kawamoto T, Kito M, Sato K, Imanishi J, Akiyama T, Kobayashi H, Nagano A, Outani H, Toki S, Nishisho T, Sasa K, Suehara Y, Kawano H, Ueda T, Morioka H. Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG). *Eur J Surg Oncol* 2022 [PMID: 36088237 DOI: 10.1016/j.ejso.2022.08.024]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 21, 2022

**First decision:** December 26, 2022

**Article in press:** January 9, 2023

**Specialty type:** Oncology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Elkady N, Egypt; Wiemer EA, Netherlands **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Table 1 Federation of the French Cancer Centres histological grading criteria**

|  |  |  |
| --- | --- | --- |
| **Differentiation (score)** | **Necrosis (score)** | **Mitotic count (score)** |
| Well (1) | Absent (0) | *n* < 101 (1) |
| Moderate (2) | < 50% (1) | *n* 10–191 (2) |
| Poor (anaplastic) (3) | ≥ 50% (2) | *n* ≥ 201 (3) |

1Number of mitoses *per* 10 high power fields.

After summing the three scores, grade 1 is defined as a total score of 2 or 3; grade 2 as a total score of 4 or 5; and grade 3 as a total score of 6 to 8.

**Table 2 American Joint Committee on Cancer classification and staging for soft tissue sarcoma, 8th Edition**

|  |  |
| --- | --- |
| **TNM classification** | **Stage**  |
| T1: Tumor ≤ 5 cm | IA: T1; N0; M0; G1 |
| T2: Tumor > 5 cm and ≤ 10 cm | IB: T2, T3, T4; N0; M0; G1 |
| T3: Tumor > 10 cm and ≤ 15 cm | II: T1; N0; M0; G2/3 |
| T4: Tumor > 15 cm | IIIA: T2; N0; M0; G2/3 |
| N0: No regional lymph node metastasis or unknown lymph node status | IIIB: T3, T4; N0; M0; G2/3 |
| N1: Regional lymph node metastasis | IV: Any T; N1; M0; any G Any T; any N; M1; any G |
| M0: No distant metastasis |  |
| M1: Distant metastasis |  |

G expresses the histological grading sum score. TNM: Tumor-Node-Metastasis.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**